Prof. Dr. Dr. Daniel Eberli
Name of the Institution
Laboratory for Urologic Tissue Engineering and Stem Cell Therapy
Faculty, Department of Urology
University Hospital Zurich
+41-44-255 95 49
Souzan Salemi, PhD, Researcher (Souzan.Salemi@usz.ch)
Christopher Millan, PhD, Researcher (Chrisopher.Millan@usz.ch)
Jenny Ann Prange, PhD, Researcher (JennyAnn.Prange@usz.ch)
Deana Mohr-Haralampieva, PhD, Clinical Project Manager and Coordinator (Deana.Haralampieva@usz.ch)
Lukas Gstrein, MD, Researcher (Lukas.Gstrein@usz.ch)
Benedikt Kranzbühler, MD, Researcher (Benedikt.Kranzbuehler@usz.ch)
Florian Schmid, MD, PhD-Student (Florian.Schmid@usz.ch)
Rosa Angelica Alves de Sousa, MSc, GMP Technician (RosaAngelica.AlvesdeSousa@usz.ch)
Elizaveta Melnichuk, GMP Technician (Elizaveta.Melnichuk@usz.ch)
Anka Baltensperger, MA, MPH, Study Nurse (Anka.Baltensperger@usz.ch)
Elena Bochenkova, MD, Intern (Elena.Bochenkova@usz.ch)
Main Field(s) of Research, Abstract
Tissue Engineering (TE) is one of the major approaches of regenerative medicine. In combination with a better understanding of structure, biology, physiology and cell culture techniques, TE offers new treatment options for patients in need of organ replacement or repair. Our research focusses on finding the optimal stem cell, improving the cell survival and the function of the developed tissue structure. We bioengineer different biomaterials for urologic tissue engineering and define the most suitable matrix to support regeneration. The culturing of stem cells in media free of animal products (xenofree) and the tracking of the implanted stem cell in the treated organs are further challenges. We conduct a clinical study to treat urinary incontinence in women by injecting autologous muscle stem cells (www.music2020.ch). Initial success with this approach encourages us to extend the cell therapy to other organ systems in the future. Our personalized medicine approach requires a multidisciplinary collaboration, which we established with other experts from UZH and ETH Zurich.
Prostate cancer is the second most common cancer in men. We aim to extend the bandwidth of prevalent cancer medicine by addressing synergistic effects of combined treatments and cell based diagnostics in prostate cancer. Over the last years, we have used multiple cancer cell models to investigate the effect of autophagy inhibitors in combination with anti-hormonal treatment. We also explored novel methods to improve prostate cancer detection by MRI and PSMA-PET technology. Over the last years, we have furthermore established a focus on cancer produced extracellular vesicles. Our current results indicate that a liquid biopsy could be used to diagnose aggressive prostate cancer and to track the treatment success.
- Improvement of mitochondria in MPC derived from old donor by alteration of mitochondrial autophagy
- Monoolein nanocarriers for intracellular oxygen delivery in muscle regeneration
- Non-invasive monitoring of muscle precursor cell differentiation in vivo by magnetic resonance imaging
- Compressed collagen seeded with autonomous smooth muscle cells (SMC) for bladder tissue engineering
- Effect of myostatin inhibitor on bladder smooth muscle regeneration
- Muscle precursor cells for the treatment of fecal incontinence
- Donor-specific adipose-derived stromal cells attenuate graft vasculopathy and rejection in rodent
- Antitumor effect of androgen synthesis inhibitors and autophagy inhibition in prostate cancer cells
- PSMA expression on prostate cancer extracellular vesicles as an indicator of positive PET imaging
- Concentration-dependent effects of dutasteride on prostate-specific membrane antigen (PSMA) expression and uptake of 177Lu-PSMA-617 in vitro
- Preclinical investigation of ARN-509 and autophagy inhibition in a castration resistant prostate cancer model
- Antitumor effect of Abiratrone and autophagy inhibition in a xenograft prostate cancer model
- Development of a liquid biopsy diagnostic for prostate cancer based on extracellular vesicles
- 3D cell culture model for discovery of cancer-specific biomarkers
- Contrast media kinetics in multiparametric MRI before radical prostatectomy predicts the probability of postoperative incontinence
TRANSLATIONAL AND CLINICAL TRIALS
- MUS.I.C. – Multisystem cell therapy for improvement of urinary continence
- Short-term dutasteride treatment improves prostate-specific membrane antigen (PSMA) imaging
- STAMPEDE - Systemic therapy for progressive or metastatic cancer of the prostate
- Interventional trial evaluating focal therapy using high intensity focused ultrasound for the treatment of prostate cancer (HIFU)
- Multiparametric transrectal ultrasound imaging as a potential biomarker for prostate cancer
Main Fields of Research, Keywords
MPCs for Tissue Engineering; Sphincter insufficiency; Stress urinary incontinence; Tissue vascularisation; Innervation; Bladder; Fat derived Stem Cells; Biomaterials – Scaffolds; Adipose derived Stem Cells; Prostate cancer
Techniques and Equipment
Cell cultures; Immunohistochemistry; Organ Bath; Viral vectors (Adenoviruses); Growth factors; MRI; Infrared sensors; Magnetic Stimulation; Electrospinning
Education and Training
We have training opportunities for research fellows, Postdocs, PhD Students, Master students and medical dissertations.
Burger IA, Muller J, Donati OF, Ferraro DA, Messerli M, Kranzbuhler B, Ter Voert E, Muehlematter UJ, Rupp NJ, Mortezavi A, Eberli D. 68Ga-PSMA-11 PET/MR detects local recurrence occult on mpMRI in prostate cancer patients after HIFU. J Nucl Med. 2019: published ahead of print.
Ferraro DA, Rupp NJ, Donati OF, Messerli M, Eberli D, Burger IA. 68Ga-PSMA-11 PET/MR can be false positive in normal prostatic tissue. Clin Nucl Med. 2019, 44 (4): e291-e293.
Kranzbühler B, Salemi S, Mortezavi A, Sulser T, Eberli D. Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells. Prostate. 2019, 79 (2): 206-214.
Mortezavi A, Krauter J, Gu A, Sonderer J, Bruhin J, Reeve KA, Held L, Donati OF, Rupp NJ, Moch H, Sulser T, Eberli D. Extensive histological sampling following focal therapy of clinically significant prostate cancer with high-intensity focused ultrasound. J Urol. 2019, accepted.
Müller J, Ferraro DA, Muehlematter UJ, Garcia Schüler HI, Kedzia S, Eberli D, Guckenberger M, Kroeze SGC, Sulser T, Schmid DM, Omlin A, Müller A, Zilli T, John H, Kranzbuehler H, Kaufmann PA, von Schulthess GK, Burger IA. Clinical impact of 68Ga-PSMA-11 PET on patient management and outcome, including all patients referred for an increase in PSA level during the first year after its clinical introduction. Eur J Nucl Med Mol Imaging. 2019, 46 (4): 889-900.
Rupp NJ, Umbricht CA, Pizzuto DA, Lenggenhager D, Topfer A, Muller J, Muhlematter UJ, Ferraro DA, Messerli M, Morand GB, Huber GF, Eberli D, Schibli R, Muller C, Burger IA. First clinico-pathological evidence of a non PSMA-related uptake mechanism for 68Ga-PSMA-11 in salivary glands. J Nucl Med. 2019: published ahead of print.
Haralampieva D, Salemi S, Betzel T, Dinulovic I, Krämer SD, Schibli R, Sulser T, Handschin C, Ametamey SM, Eberli D. Injected human muscle precursor cells overexpressing PGC-1α enhance functional muscle regeneration after trauma. Stem Cells Intl. 2018: 11 pages.
Mortezavi A, Märzendorfer O, Donati OF, Rizzi G, Rupp NJ, Wettstein MS, Gross O, Sulser T, Hermanns T, Eberli D. Diagnostic accuracy of multiparametric magnetic resonance imaging and fusion guided targeted biopsy evaluated by transperineal template saturation prostate biopsy for the detection and characterization of prostate cancer. J Urol. 2018, 200 (2): 309-318.
Pizzuto DA, Müller J, Mühlematter U, Rupp NJ, Töpfer A, Mortezavi A, Nagel H, Kranzbühler B, Eberli D, Burger IA. The central zone has increased 68Ga-PSMA-11 uptake: “Mickey Mouse ears” can be hot on 68Ga-PSMA-11 PET. Eur J Nucl Med Mol Imaging. 2018, 45 (8): 1335-1343.
Barth BK, De Visschere PJL, Cornelius A, Nicolau C, Vargas HA, Eberli D, Donati OF. Detection of clinically significant prostate cancer: Short dual-pulse sequence versus standard multiparametric MR Imaging - A multireader study. Radiology. 2017, 284 (3): 725-736.
Evrova O, Hosseini V, Milleret V, Palazzolo G, Zenobi-Wong M, Sulser T, Buschmann J, Eberli D. Hybrid randomly electrospun poly(lactic-co-glycolic acid):poly(ethylene oxide) (PLGA:PEO) fibrous scaffolds enhancing myoblast differentiation and alignment. ACS Appl Mater Interfaces. 2016, 8 (46): 31574-31586.
Haralampieva D, Betzel T, Dinulovic I, Salemi S, Stoelting M, Krämer SD, Schibli R, Sulser T, Handschin C, Eberli D, Ametamey SM. Noninvasive PET imaging and tracking of engineered human muscle precursor cells for skeletal muscle tissue engineering. J Nucl Med. 2016, 57 (9): 1467-1473.
Rottmar M, Haralampieva D, Salemi S, Eberhardt C, Wurnig MC, Boss A, Eberli D. Magnetization transfer MR imaging to monitor muscle tissue formation during myogenic in vivo differentiation of muscle precursor cells. Radiology. 2016, 281 (2): 436-443.
Sakar MS, Eyckmans J, Pieters R, Eberli D, Nelson BJ, Chen CS. Cellular forces and matrix assembly coordinate fibrous tissue repair. Nat Commun. 2016, 7.
Azzabi F, Rottmar M, Jovaisaite V, Rudin M, Sulser T, Boss A, Eberli D. Viability, differentiation capacity, and detectability of super-paramagnetic iron oxide-labeled muscle precursor cells for magnetic-resonance imaging. Tissue Eng Part C Methods. 2015, 21 (2): 182-191.
Fürer K, Eberli D, Betschart C, Brenneisen R, De Mieri M, Hamburger M, Mennet-Von Eiff M, Potterat O, Schnelle M, Simões-Wüst AP, Von Mandach U. Inhibition of porcine detrusor contractility by the flavonoid fraction of Bryophyllum pinnatum - A potential phytotherapeutic drug for the treatment of the overactive bladder syndrome. Phytomedicine. 2015, 22 (1): 158-164.
Handschin C, Mortezavi A, Plock J, Eberli D. External physical and biochemical stimulation to enhance skeletal muscle bioengineering. Adv Drug Deliv Rev. 2015, 82: 168-175.
Kamat P, Schweizer R, Kaenel P, Salemi S, Calcagni M, Giovanoli P, Gorantla VS, Eberli D, Andres AC, Plock JA. Human adipose-derived mesenchymal stromal cells may promote breast cancer progression and metastatic spread. Plast Reconstr Surg. 2015, 136 (1): 76-84.
Eberli D, Lee SJ, Traweger A (Eds.). Organ tissue engineering, in progress, Springer International Publishing, Heidelberg, Germany.
Eberli D (Ed.). Cells and biomaterials in regenerative medicine, 2014, IntechOpen, London, UK. ISBN 978-953-51-1731-5
Eberli D (Ed.). Regenerative medicine and tissue engineering - cells and biomaterials, 2011, IntechOpen, London, UK. ISBN 978-953-307-663-8
- HORIZON2020 (EU)
- “SNF, Schweizer National Fonds” 323230_126230/1
- Commission for Technology and Innovations CTI
- Baugarten Stiftung
- Dr. Angela Reiffer-Stiftung
- Foundation Gaydoul